| BCG vaccine | 1977 | Immunologicals > Vaccines | Need for immunization against tuberculosis | L03AX03 |
| Ebola vaccine | 2025 | Immunologicals > Vaccines | Need for immunization against certain single viral diseases | J07BX02 |
| Japanese encephalitis vaccine | 2007 | Immunologicals > Vaccines | Need for immunization against certain single viral diseases | J07BA02, J07BA03 |
| Medicines for COVID-19 | 2023 | Medicines for COVID-19 | COVID-19 | |
| abacavir | 2002 | Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors | Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified | J05AF06 |
| abacavir + dolutegravir + lamivudine | 2025 | Fixed-dose combinations of antiretrovirals | Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified | J05AR13 |
| abacavir + lamivudine | 2015 | Fixed-dose combinations of antiretrovirals | Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified | J05AR02 |
| abiraterone | 2019 | Hormones and antihormones | Malignant neoplasms of prostate | L02BX03 |
| acamprosate calcium | 2023 | Medicines for alcohol use disorders | Disorders due to use of alcohol | N07BB03 |
| acenocoumarol | 2025 | Medicines affecting coagulation | Venous thromboembolism; Cerebral ischaemic stroke due to embolic occlusion; Atrial fibrillation; Other specified diseases of arteries or arterioles | |
| acetazolamide | 1977 | Ophthalmological preparations > Miotics and antiglaucoma medicines | Primary open-angle glaucoma | S01EC01 |
| acetic acid | 2009 | Ear, nose and throat medicines [c] | Infectious diseases of external ear | S02AA10 |
| acetylcysteine | 1999 | Antidotes and other substances used in poisonings > Specific | Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs | V03AB23 |
| acetylsalicylic acid | 1977 | Medicines for acute migraine attacks | Migraine; Acute myocardial infarction; Cerebral ischaemic stroke; Mucocutaneous lymph node syndrome; Juvenile idiopathic arthritis; Acute rheumatic fever without mention of heart involvement; Pain | N02BA01, B01AC06 |
| acetylsalicylic acid + atorvastatin + ramipril | 2023 | Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease | Atherosclerotic chronic arterial occlusive disease; Chronic ischaemic heart disease; Cerebral ischaemic stroke | C10BX06 |
| acetylsalicylic acid + simvastatin + ramipril + atenolol + hydrochlorothiazide | 2023 | Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease | Atherosclerotic chronic arterial occlusive disease; Chronic ischaemic heart disease; Cerebral ischaemic stroke | |
| aciclovir | 1997 | Ophthalmological preparations > Anti-infective agents | Herpes simplex keratitis; Zoster; Herpes simplex infections; Varicella | S01AD03, J05AB01 |
| aclidinium | 2025 | Antiasthmatic and medicines for chronic obstructive pulmonary disease | Chronic obstructive pulmonary disease | |
| activated charcoal | 1977 | Antidotes and other substances used in poisonings > Non-specific | Unspecified injury, poisoning or certain other consequences of external causes | A07BA01 |
| adalimumab | 2019 | Immunomodulators for non-malignant disease | Axial spondyloarthritis; Crohn disease site; Rheumatoid arthritis; Juvenile idiopathic arthritis; Psoriasis of unspecified type | L04AB04 |
| afatinib | 2019 | Targeted therapies | Other specified malignant neoplasms of bronchus or lung | |
| albendazole | 1989 | Intestinal anthelminthics | Echinococcosis; Cysticercosis; Hookworm diseases; Trichuriasis; Ascariasis; Enterobiasis; Other specified echinococcosis; Cysticercosis of central nervous system; Lymphatic filariasis | P02CA03 |
| alcohol based hand rub | 2015 | Disinfectants | Denatured alcohol | D08AX08 |
| all-trans retinoic acid | 2015 | Targeted therapies | Acute myeloid leukaemia with recurrent genetic abnormalities | L01XF01 |
| allopurinol | 1977 | Medicines used to treat gout | Gout; Tumour lysis syndrome | M04AA01 |
| alprostadil (prostaglandin E1) | 2009 | Medicines administered to the neonate [c] | Other specified congenital anomaly of great arteries including arterial duct | C01EA01 |
| alteplase | 2019 | Thrombolytic medicines | Cerebral ischaemic stroke | B01AD02 |
| amidotrizoate | 1977 | Diagnostic agents > Radiocontrast media | Amidotrizoate | V08AA01 |
| amikacin | 1999 | Ophthalmological preparations > Anti-infective agents | Other specified conjunctivitis; Infectious blepharitis; Acute pyelonephritis (severe); Neutropaenia (high-risk); Inflammatory or other diseases of prostate (severe); Multi-drug resistant Mycobacterium tuberculosis | J01GB06 |
| amiloride | 1979 | Diuretics | Oedema; Ascites | C03DB01 |
| amiodarone | 2009 | Antiarrhythmic medicines | Cardiac arrhythmia | C01BD01 |
| amitriptyline | 1977 | Medicines for other common symptoms in palliative care | Palliative care; Depressive disorders | N06AA09 |
| amlodipine | 2005 | Antihypertensive medicines | Essential hypertension | C08CA01 |
| amodiaquine - sulfadoxine + pyrimethamine | 2019 | Antimalarial medicines > Medicines for chemoprevention | Malaria | P01BA06, P01BD51 |
| amoxicillin | 1989 | Access group antibiotics | Acute pharyngitis; Periapical abscess without sinus; Acute sinusitis; Acute otitis media; Chronic obstructive pulmonary disease with acute exacerbation; Sepsis without septic shock; Acute malnutrition in infants, children or adolescents (uncomplicated) [children]; Acute malnutrition in infants, children or adolescents (complicated) [children]; Bacterial pneumonia (Community-acquired pneumonia - mild to moderate); Bacterial pneumonia (Community-acquired pneumonia - severe) [children]; Bacterial meningitis | J01CA04 |
| amoxicillin + clavulanic acid | 1997 | Access group antibiotics | Bacterial pneumonia (Community-acquired pneumonia - severe) [children]; Acute sinusitis; Other specified pneumonia (Hospital-acquired pneumonia); Chronic obstructive pulmonary disease with acute exacerbation; Neutropaenia (low-risk); Peritoneal abscess (mild-moderate); Peritonitis (mild-moderate); Infectious cystitis; Bacterial cellulitis, erysipelas or lymphangitis; Bacterial pneumonia (Community-acquired pneumonia - mild to moderate); Bacterial pneumonia (Community-acquired pneumonia - severe); Bacterial infection of joint; Acute otitis media; Other specified prophylactic measures; Osteomyelitis or osteitis; Multi-drug resistant Mycobacterium tuberculosis | J01CR02 |
| amphotericin B | 1977 | Antifungal medicines | Candidosis; Blastomycosis; Cryptococcosis; Coccidioidomycosis; Aspergillosis; Sporotrichosis; Histoplasmosis; Visceral leishmaniasis | J02AA01 |
| ampicillin | 1977 | Access group antibiotics | Bacterial pneumonia (Community-acquired pneumonia - severe) [children]; Acute malnutrition in infants, children or adolescents (complicated) [children]; Sepsis without septic shock; Peritoneal abscess (mild-moderate); Peritoneal abscess (severe); Peritonitis (mild-moderate); Peritonitis (severe); Bacterial meningitis | J01CA01 |
| anastrozole | 2015 | Hormones and antihormones | Malignant neoplasms of breast; Other specified malignant neoplasms of breast; Female infertility without specification whether primary or secondary | L02BG03 |
| anidulafungin | 2021 | Antifungal medicines | Systemic or invasive candidosis | |
| ansuvimab | 2023 | Medicines for Ebola virus disease | Ebola virus disease | J06BD04 |
| anti-D immunoglobulin | 1977 | Human immunoglobulins | Maternal care for red cell antibodies; Rh incompatibility reaction | J06BB01 |
| anti-rabies immunoglobulin | 1991 | Human immunoglobulins | Rabies | J06BB05 |
| anti-rabies virus monoclonal antibodies | 2021 | Immunologicals > Sera, immunoglobulins and monoclonal antibodies | Rabies | |
| anti-tetanus immunoglobulin | 1984 | Human immunoglobulins | Tetanus | J06BB02 |
| antivenom immunoglobulin | 2007 | Immunologicals > Sera, immunoglobulins and monoclonal antibodies | Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified | |
| apixaban | 2019 | Medicines affecting coagulation | Other specified atrial fibrillation; Venous thromboembolism | |
| aprepitant | 2019 | Antiemetic medicines | Nausea or vomiting | A04AD12 |
| aripiprazole | 2023 | Medicines for psychotic disorders | Schizophrenia or other primary psychotic disorders | |
| arpraziquantel | 2025 | Antischistosomals and other antitrematode medicines | Schistosomiasis | |